1312MO Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: Overall survival data from the first line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (phase II).

MLA

Carcereny, E., et al. “1312MO Combining the Antigen-Presenting Cell Activator Eftilagimod Alpha (Soluble LAG-3) and Pembrolizumab: Overall Survival Data from the First Line Non-Small Cell Lung Carcinoma (NSCLC) Cohort of TACTI-002 (Phase II).” Annals of Oncology, vol. 34, Oct. 2023, p. S754. EBSCOhost, https://doi.org/10.1016/j.annonc.2023.09.2346.

APA

Carcereny, E., Felip, E., Majem, M., Doger de Spéville, B., Clay, T. D., Bondarenko, I., Peguero, J., Cobo Dols, M., Forster, M. D., Ursol, G., Kalinka, E., Garcia Ledo, G. M., Vila Martinez, L., Iams, W., Krebs, M. G., Kefas, J., Efthymiadis, K., Perera, S., Mueller, C., & Triebel, F. (2023). 1312MO Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: Overall survival data from the first line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (phase II). Annals of Oncology, 34, S754. https://doi.org/10.1016/j.annonc.2023.09.2346

Chicago

Carcereny, E., E. Felip, M. Majem, B. Doger de Spéville, T.D. Clay, I. Bondarenko, J. Peguero, et al. 2023. “1312MO Combining the Antigen-Presenting Cell Activator Eftilagimod Alpha (Soluble LAG-3) and Pembrolizumab: Overall Survival Data from the First Line Non-Small Cell Lung Carcinoma (NSCLC) Cohort of TACTI-002 (Phase II).” Annals of Oncology 34 (October): S754. doi:10.1016/j.annonc.2023.09.2346.